Beyond the gut–kidney axis, the same drug pairing appears to benefit the gut–liver axis: A 2023 review of NAFLD/MAFLD trials concluded that the combination improves steatosis and hepatic inflammation more than either class individually—SGLT2is primarily diminish hepatic fat, while GLP-1 RAs temper inflammatory signaling [201]. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.